Intriguingly, copper‐specific chelators or inhibitors of ATOX1 and CCS have been demonstrated to be capable of suppressing the proliferation of several cancer cells.9, 12, 13 Tetrathiomolybdate (TM), a well‐tolerated copper chelator, is shown to inhibit tumour angiogenesis and growth in animal models and clinical trials.14, 15, 16, 17 Therefore, copper deprivation has been considered a hopeful strategy for the therapy of cancers with high copper content. This evidence concerns the gene CCS and cancer.